All Resources
Our resource hub to discover reports, policy papers and other forms of informative content
The Suspension and Reformulation of the PMPRB Guidelines is Urgently Required: IMC Response to PMPRB 2022 Guidelines Proposals
Innovative Medicines Canada has submitted formal feedback to the Patented Medicine Prices Review Board’s (PMPRB) revised Draft Guidelines public consultation, calling for a suspension of the planned implementation to ensure meaningful stakeholder consultation and a thorough impact analysis.
Letter to The Honourable Jean-Yves Duclos, P.C., M.P.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
Letter to The Hon. Chrystia Freeland, P.C., M.P.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
*Cette lettre est disponible en anglais seulement.
Letter to The Honourable Mary Ng, P.C., M.P.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
*Cette lettre est disponible en anglais seulement.
Ministerial PMPRB Guideline Letter to The Hon. François-Philippe Champagne, P.C., M.P.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
IMC Response to PMPRB Interim Approach Consultation
IMC’s members continue to have significant concerns regarding changes to the PMPRB and future Guidelines that will implement the revised schedule of international reference countries.
PMPRB Notice and Comment Response
Innovative Medicines Canada opposes a July 15, 2021 proposal to change international price tests for existing medicines and their line extensions from the highest of the international schedule to the median.
